YAP/TAZ for cancer therapy: Opportunities and challenges (Review)
- Authors:
- Liwen Guo
- Lisong Teng
-
Affiliations: Department of Surgical Oncology, The 1st Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang 310003, P.R. China - Published online on: February 5, 2015 https://doi.org/10.3892/ijo.2015.2877
- Pages: 1444-1452
This article is mentioned in:
Abstract
 |
 |
|
Harvey K and Tapon N: The Salvador-Warts-Hippo pathway - an emerging tumour-suppressor network. Nat Rev Cancer. 7:182–191. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Watson KL, Justice RW and Bryant PJ: Drosophila in cancer research: The first fifty tumor suppressor genes. J Cell Sci (Suppl). 18:19–33. 1994. View Article : Google Scholar | |
|
Halder G and Johnson RL: Hippo signaling: Growth control and beyond. Development. 138:9–22. 2011. View Article : Google Scholar : | |
|
Mo JS, Park HW and Guan KL: The Hippo signaling pathway in stem cell biology and cancer. EMBO Rep. 15:642–656. 2014.PubMed/NCBI | |
|
Justice RW, Zilian O, Woods DF, Noll M and Bryant PJ: The Drosophila tumor suppressor gene warts encodes a homolog of human myotonic dystrophy kinase and is required for the control of cell shape and proliferation. Genes Dev. 9:534–546. 1995. View Article : Google Scholar : PubMed/NCBI | |
|
Wu S, Huang J, Dong J and Pan D: Hippo encodes a Ste-20 family protein kinase that restricts cell proliferation and promotes apoptosis in conjunction with salvador and warts. Cell. 114:445–456. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Udan RS, Kango-Singh M, Nolo R, Tao C and Halder G: Hippo promotes proliferation arrest and apoptosis in the Salvador/Warts pathway. Nat Cell Biol. 5:914–920. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Huang J, Wu S, Barrera J, Matthews K and Pan D: The Hippo signaling pathway coordinately regulates cell proliferation and apoptosis by inactivating Yorkie, the Drosophila Homolog of YAP. Cell. 122:421–434. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Thompson BJ and Cohen SM: The Hippo pathway regulates the bantam microRNA to control cell proliferation and apoptosis in Drosophila. Cell. 126:767–774. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Koontz LM, Liu-Chittenden Y, Yin F, Zheng Y, Yu J, Huang B, Chen Q, Wu S and Pan D: The Hippo effector Yorkie controls normal tissue growth by antagonizing scalloped-mediated default repression. Dev Cell. 25:388–401. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Hong W and Guan KL: The YAP and TAZ transcription co-activators: Key downstream effectors of the mammalian Hippo pathway. Semin Cell Dev Biol. 23:785–793. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Harvey KF, Zhang X and Thomas DM: The Hippo pathway and human cancer. Nat Rev Cancer. 13:246–257. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Stanger BZ: Quit your YAPing: A new target for cancer therapy. Genes Dev. 26:1263–1267. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Wang L, Chen Z, Wang Y, et al: WWTR1 promotes cell proliferation and inhibits apoptosis through cyclin A and CTGF regulation in non-small cell lung cancer. Tumour Biol. 35:463–468. 2014. View Article : Google Scholar | |
|
Yu FX, Zhang Y, Park HW, Jewell JL, Chen Q, Deng Y, Pan D, Taylor SS, Lai ZC and Guan KL: Protein kinase A activates the Hippo pathway to modulate cell proliferation and differentiation. Genes Dev. 27:1223–1232. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Kim NG, Koh E, Chen X and Gumbiner BM: E-cadherin mediates contact inhibition of proliferation through Hippo signaling-pathway components. Proc Natl Acad Sci USA. 108:11930–11935. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Yue T, Tian A and Jiang J: The cell adhesion molecule echinoid functions as a tumor suppressor and upstream regulator of the Hippo signaling pathway. Dev Cell. 22:255–267. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Verghese S, Waghmare I, Kwon H, Hanes K and Kango-Singh M: Scribble acts in the Drosophila fat-hippo pathway to regulate warts activity. PLoS One. 7:e471732012. View Article : Google Scholar : PubMed/NCBI | |
|
Konsavage WM Jr and Yochum GS: Intersection of Hippo/YAP and Wnt/β-catenin signaling pathways. Acta Biochim Biophys Sin (Shanghai). 45:71–79. 2013. View Article : Google Scholar | |
|
Yu FX, Zhao B, Panupinthu N, et al: Regulation of the Hippo-YAP pathway by G-protein-coupled receptor signaling. Cell. 150:780–791. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Tumaneng K, Schlegelmilch K, Russell RC, Yimlamai D, Basnet H, Mahadevan N, Fitamant J, Bardeesy N, Camargo FD and Guan KL: YAP mediates crosstalk between the Hippo and PI(3)K-TOR pathways by suppressing PTEN via miR-29. Nat Cell Biol. 14:1322–1329. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Dai X, She P, Chi F, et al: Phosphorylation of angiomotin by Lats1/2 kinases inhibits F-actin binding, cell migration, and angiogenesis. J Biol Chem. 288:34041–34051. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Hong W: Angiomotin’g YAP into the nucleus for cell proliferation and cancer development. Sci Signal. 6:pe272013. | |
|
Sudol M: Yes-associated protein (YAP65) is a proline-rich phosphoprotein that binds to the SH3 domain of the Yes proto-oncogene product. Oncogene. 9:2145–2152. 1994.PubMed/NCBI | |
|
Sudol M, Bork P, Einbond A, Kastury K, Druck T, Negrini M, Huebner K and Lehman D: Characterization of the mammalian YAP (Yes-associated protein) gene and its role in defining a novel protein module, the WW domain. J Biol Chem. 270:14733–14741. 1995. View Article : Google Scholar : PubMed/NCBI | |
|
Gaffney CJ, Oka T, Mazack V, et al: Identification, basic characterization and evolutionary analysis of differentially spliced mRNA isoforms of human YAP1 gene. Gene. 509:215–222. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Morin-Kensicki EM, Boone BN, Howell M, Stonebraker JR, Teed J, Alb JG, Magnuson TR, O’Neal W and Milgram SL: Defects in yolk sac vasculogenesis, chorioallantoic fusion, and embryonic axis elongation in mice with targeted disruption of Yap65. Mol Cell Biol. 26:77–87. 2006. View Article : Google Scholar : | |
|
Kanai F, Marignani PA, Sarbassova D, et al: TAZ: A novel transcriptional co-activator regulated by interactions with 14-3-3 and PDZ domain proteins. EMBO J. 19:6778–6791. 2000. View Article : Google Scholar : PubMed/NCBI | |
|
Oka T and Sudol M: Nuclear localization and pro-apoptotic signaling of YAP2 require intact PDZ-binding motif. Genes Cells. 14:607–615. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Remue E, Meerschaert K, Oka T, Boucherie C, Vandekerckhove J, Sudol M and Gettemans J: TAZ interacts with zonula occludens-1 and -2 proteins in a PDZ-1 dependent manner. FEBS Lett. 584:4175–4180. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Sawada A, Kiyonari H, Ukita K, Nishioka N, Imuta Y and Sasaki H: Redundant roles of Tead1 and Tead2 in notochord development and the regulation of cell proliferation and survival. Mol Cell Biol. 28:3177–3189. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Lamar JM, Stern P, Liu H, Schindler JW, Jiang ZG and Hynes RO: The Hippo pathway target, YAP, promotes metastasis through its TEAD-interaction domain. Proc Natl Acad Sci USA. 109:E2441–E2450. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang H, Liu CY, Zha ZY, Zhao B, Yao J, Zhao S, Xiong Y, Lei QY and Guan KL: TEAD transcription factors mediate the function of TAZ in cell growth and epithelial-mesenchymal transition. J Biol Chem. 284:13355–13362. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Zhao B, Ye X, Yu J, et al: TEAD mediates YAP-dependent gene induction and growth control. Genes Dev. 22:1962–1971. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Fossdal R, Jonasson F, Kristjansdottir GT, Kong A, Stefansson H, Gosh S, Gulcher JR and Stefansson K: A novel TEAD1 mutation is the causative allele in Sveinsson’s chorioretinal atrophy (helicoid peripapillary chorioretinal degeneration). Hum Mol Genet. 13:975–981. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Yagi R, Chen LF, Shigesada K, Murakami Y and Ito Y: A WW domain-containing yes-associated protein (YAP) is a novel transcriptional co-activator. EMBO J. 18:2551–2562. 1999. View Article : Google Scholar : PubMed/NCBI | |
|
Zaidi SK, Sullivan AJ, Medina R, Ito Y, van Wijnen AJ, Stein JL, Lian JB and Stein GS: Tyrosine phosphorylation controls Runx2-mediated subnuclear targeting of YAP to repress transcription. EMBO J. 23:790–799. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Park KS, Whitsett JA, Di Palma T, Hong JH, Yaffe MB and Zannini M: TAZ interacts with TTF-1 and regulates expression of surfactant protein-C. J Biol Chem. 279:17384–17390. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Murakami M, Nakagawa M, Olson EN and Nakagawa O: A WW domain protein TAZ is a critical coactivator for TBX5, a transcription factor implicated in Holt-Oram syndrome. Proc Natl Acad Sci USA. 102:18034–18039. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Varelas X, Sakuma R, Samavarchi-Tehrani P, Peerani R, Rao BM, Dembowy J, Yaffe MB, Zandstra PW and Wrana JL: TAZ controls Smad nucleocytoplasmic shuttling and regulates human embryonic stem-cell self-renewal. Nat Cell Biol. 10:837–848. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Hong JH, Hwang ES, McManus MT, et al: TAZ, a transcriptional modulator of mesenchymal stem cell differentiation. Science. 309:1074–1078. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Zhao D, Zhi X, Zhou Z and Chen C: TAZ antagonizes the WWP1-mediated KLF5 degradation and promotes breast cell proliferation and tumorigenesis. Carcinogenesis. 33:59–67. 2012. View Article : Google Scholar | |
|
Strano S, Munarriz E, Rossi M, Castagnoli L, Shaul Y, Sacchi A, Oren M, Sudol M, Cesareni G and Blandino G: Physical interaction with Yes-associated protein enhances p73 transcriptional activity. J Biol Chem. 276:15164–15173. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Komuro A, Nagai M, Navin NE and Sudol M: WW domain-containing protein YAP associates with ErbB-4 and acts as a co-transcriptional activator for the carboxyl-terminal fragment of ErbB-4 that translocates to the nucleus. J Biol Chem. 278:33334–33341. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Dong J, Feldmann G, Huang J, Wu S, Zhang N, Comerford SA, Gayyed MF, Anders RA, Maitra A and Pan D: Elucidation of a universal size-control mechanism in Drosophila and mammals. Cell. 130:1120–1133. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Zhao B, Li L, Tumaneng K, Wang CY and Guan KL: A coordinated phosphorylation by Lats and CK1 regulates YAP stability through SCF(beta-TRCP). Genes Dev. 24:72–85. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Huang W, Lv X, Liu C, Zha Z, Zhang H, Jiang Y, Xiong Y, Lei QY and Guan KL: The N-terminal phosphodegron targets TAZ/WWTR1 protein for SCFβ-TrCP-dependent degradation in response to phosphatidylinositol 3-kinase inhibition. J Biol Chem. 287:26245–26253. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Liu X, Yang N, Figel SA, Wilson KE, Morrison CD, Gelman IH and Zhang J: PTPN14 interacts with and negatively regulates the oncogenic function of YAP. Oncogene. 32:1266–1273. 2013. View Article : Google Scholar | |
|
Zhao B, Li L, Lu Q, Wang LH, Liu CY, Lei Q and Guan KL: Angiomotin is a novel Hippo pathway component that inhibits YAP oncoprotein. Genes Dev. 25:51–63. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Oka T, Schmitt AP and Sudol M: Opposing roles of angiomotin-like-1 and zona occludens-2 on pro-apoptotic function of YAP. Oncogene. 31:128–134. 2012. View Article : Google Scholar | |
|
Hamaratoglu F, Gajewski K, Sansores-Garcia L, Morrison C, Tao C and Halder G: The Hippo tumor-suppressor pathway regulates apical-domain size in parallel to tissue growth. J Cell Sci. 122:2351–2359. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Overholtzer M, Zhang J, Smolen GA, Muir B, Li W, Sgroi DC, Deng CX, Brugge JS and Haber DA: Transforming properties of YAP, a candidate oncogene on the chromosome 11q22 amplicon. Proc Natl Acad Sci USA. 103:12405–12410. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Cordenonsi M, Zanconato F, Azzolin L, et al: The Hippo transducer TAZ confers cancer stem cell-related traits on breast cancer cells. Cell. 147:759–772. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Chan SW, Lim CJ, Guo K, Ng CP, Lee I, Hunziker W, Zeng Q and Hong W: A role for TAZ in migration, invasion, and tumorigenesis of breast cancer cells. Cancer Res. 68:2592–2598. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Piccolo S, Cordenonsi M and Dupont S: Molecular pathways: YAP and TAZ take center stage in organ growth and tumorigenesis. Clin Cancer Res. 19:4925–4930. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Wang L, Shi S, Guo Z, Zhang X, Han S, Yang A, Wen W and Zhu Q: Overexpression of YAP and TAZ is an independent predictor of prognosis in colorectal cancer and related to the proliferation and metastasis of colon cancer cells. PLoS One. 8:e655392013. View Article : Google Scholar : PubMed/NCBI | |
|
Lu L, Li Y, Kim SM, et al: Hippo signaling is a potent in vivo growth and tumor suppressor pathway in the mammalian liver. Proc Natl Acad Sci USA. 107:1437–1442. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Lee KP, Lee JH, Kim TS, et al: The Hippo-Salvador pathway restrains hepatic oval cell proliferation, liver size, and liver tumorigenesis. Proc Natl Acad Sci USA. 107:8248–8253. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Avruch J, Zhou D and Bardeesy N: YAP oncogene over-expression supercharges colon cancer proliferation. Cell Cycle. 11:1090–1096. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
de Cristofaro T, Di Palma T, Ferraro A, Corrado A, Lucci V, Franco R, Fusco A and Zannini M: TAZ/WWTR1 is over-expressed in papillary thyroid carcinoma. Eur J Cancer. 47:926–933. 2011. View Article : Google Scholar | |
|
Yuen HF, McCrudden CM, Huang YH, Tham JM, Zhang X, Zeng Q, Zhang SD and Hong W: TAZ expression as a prognostic indicator in colorectal cancer. PLoS One. 8:e542112013. View Article : Google Scholar : PubMed/NCBI | |
|
Wang Y, Dong Q, Zhang Q, Li Z, Wang E and Qiu X: Overexpression of yes-associated protein contributes to progression and poor prognosis of non-small-cell lung cancer. Cancer Sci. 101:1279–1285. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Xu MZ, Yao TJ, Lee NP, Ng IO, Chan YT, Zender L, Lowe SW, Poon RT and Luk JM: Yes-associated protein is an independent prognostic marker in hepatocellular carcinoma. Cancer. 115:4576–4585. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Xie M, Zhang L, He CS, Hou JH, Lin SX, Hu ZH, Xu F and Zhao HY: Prognostic significance of TAZ expression in resected non-small cell lung cancer. J Thorac Oncol. 7:799–807. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Yue G, Sun X, Gimenez-Capitan A, Shen J, Yu L, Teixido C, Guan W, Rosell R, Liu B and Wei J: TAZ is highly expressed in gastric signet ring cell carcinoma. Biomed Res Int. 2014:3930642014. View Article : Google Scholar : PubMed/NCBI | |
|
Lam-Himlin DM, Daniels JA, Gayyed MF, Dong J, Maitra A, Pan D, Montgomery EA and Anders RA: The hippo pathway in human upper gastrointestinal dysplasia and carcinoma: A novel oncogenic pathway. Int J Gastrointest Cancer. 37:103–109. 2006. | |
|
Zhao B, Li L, Wang L, Wang CY, Yu J and Guan KL: Cell detachment activates the Hippo pathway via cytoskeleton reorganization to induce anoikis. Genes Dev. 26:54–68. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Yuan M, Tomlinson V, Lara R, et al: Yes-associated protein (YAP) functions as a tumor suppressor in breast. Cell Death Differ. 15:1752–1759. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Danovi SA, Rossi M, Gudmundsdottir K, Yuan M, Melino G and Basu S: Yes-associated protein (YAP) is a critical mediator of c-Jun-dependent apoptosis. Cell Death Differ. 15:217–219. 2008. View Article : Google Scholar | |
|
Lai D, Ho KC, Hao Y and Yang X: Taxol resistance in breast cancer cells is mediated by the hippo pathway component TAZ and its downstream transcriptional targets Cyr61 and CTGF. Cancer Res. 71:2728–2738. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Liu-Chittenden Y, Huang B, Shim JS, Chen Q, Lee SJ, Anders RA, Liu JO and Pan D: Genetic and pharmacological disruption of the TEAD-YAP complex suppresses the oncogenic activity of YAP. Genes Dev. 26:1300–1305. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Jiao S, Wang H, Shi Z, et al: A peptide mimicking VGLL4 function acts as a YAP antagonist therapy against gastric cancer. Cancer Cell. 25:166–180. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Zhou Z, Hu T, Xu Z, et al: Targeting Hippo pathway by specific interruption of YAP-TEAD interaction using cyclic YAP-like peptides. FASEB J. Nov 10–2014.(Epub ahead of print). PubMed/NCBI | |
|
Anand R, Maksimoska J, Pagano N, Wong EY, Gimotty PA, Diamond SL, Meggers E and Marmorstein R: Toward the development of a potent and selective organoruthenium mammalian sterile 20 kinase inhibitor. J Med Chem. 52:1602–1611. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Rosenbluh J, Nijhawan D, Cox AG, et al: β-Catenin-driven cancers require a YAP1 transcriptional complex for survival and tumorigenesis. Cell. 151:1457–1473. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Frangou C, Li YW, Shen H, et al: Molecular profiling and computational network analysis of TAZ-mediated mammary tumorigenesis identifies actionable therapeutic targets. Oncotarget. 5:12166–12176. 2014.PubMed/NCBI | |
|
Sansores-Garcia L, Bossuyt W, Wada K, Yonemura S, Tao C, Sasaki H and Halder G: Modulating F-actin organization induces organ growth by affecting the Hippo pathway. EMBO J. 30:2325–2335. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Fernández BG, Gaspar P, Brás-Pereira C, Jezowska B, Rebelo SR and Janody F: Actin-Capping Protein and the Hippo pathway regulate F-actin and tissue growth in Drosophila. Development. 138:2337–2346. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Wada K, Itoga K, Okano T, Yonemura S and Sasaki H: Hippo pathway regulation by cell morphology and stress fibers. Development. 138:3907–3914. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Thomasy SM, Morgan JT, Wood JA, Murphy CJ and Russell P: Substratum stiffness and latrunculin B modulate the gene expression of the mechanotransducers YAP and TAZ in human trabecular meshwork cells. Exp Eye Res. 113:66–73. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Kono K, Tamashiro DA and Alarcon VB: Inhibition of RHO-ROCK signaling enhances ICM and suppresses TE characteristics through activation of Hippo signaling in the mouse blastocyst. Dev Biol. 394:142–155. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Miller E, Yang J, DeRan M, Wu C, Su AI, Bonamy GM, Liu J, Peters EC and Wu X: Identification of serum-derived sphin-gosine-1-phosphate as a small molecule regulator of YAP. Chem Biol. 19:955–962. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Mo JS, Yu FX, Gong R, Brown JH and Guan KL: Regulation of the Hippo-YAP pathway by protease-activated receptors (PARs). Genes Dev. 26:2138–2143. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Fleming JK, Wojciak JM, Campbell MA and Huxford T: Biochemical and structural characterization of lysophosphatidic Acid binding by a humanized monoclonal antibody. J Mol Biol. 408:462–476. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Ponnusamy S, Selvam SP, Mehrotra S, Kawamori T, Snider AJ, Obeid LM, Shao Y, Sabbadini R and Ogretmen B: Communication between host organism and cancer cells is transduced by systemic sphingosine kinase 1/sphingosine 1-phosphate signalling to regulate tumour metastasis. EMBO Mol Med. 4:761–775. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Bao Y, Nakagawa K, Yang Z, Ikeda M, Withanage K, Ishigami-Yuasa M, Okuno Y, Hata S, Nishina H and Hata Y: A cell-based assay to screen stimulators of the Hippo pathway reveals the inhibitory effect of dobutamine on the YAP-dependent gene transcription. J Biochem. 150:199–208. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Azzolin L, Zanconato F, Bresolin S, Forcato M, Basso G, Bicciato S, Cordenonsi M and Piccolo S: Role of TAZ as mediator of Wnt signaling. Cell. 151:1443–1456. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Huang SM, Mishina YM, Liu S, et al: Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling. Nature. 461:614–620. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Lau T, Chan E, Callow M, et al: A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth. Cancer Res. 73:3132–3144. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Sorrentino G, Ruggeri N, Specchia V, et al: Metabolic control of YAP and TAZ by the mevalonate pathway. Nat Cell Biol. 16:357–366. 2014. View Article : Google Scholar : PubMed/NCBI |
